StageZero Life Sciences Ltd (NASDAQ:SZLSF) | Finanzwire

Basculer en Français

8298	Companies
114933	Keywords
55342	Articles
62466	Press releases

Headlines Articles Press releases StageZero Life Sciences Ltd

Home
Companies
StageZero Life Sciences Ltd

BRIEF

published on 07/09/2024 at 23:20, 4 months 11 days ago

StageZero Life Sciences Updates on Filing of Full Year 2023 Financials

Ontario Securities Commission FFCTO Audit Completion Financial Filings StageZero Life Sciences
PRESS RELEASE

published on 07/09/2024 at 23:15, 4 months 11 days ago

StageZero Life Sciences Announces Update on Filing of Full Year 2023 Financials Under the Failure To File Cease Trade Order
StageZero Life Sciences provides an update on filing full year 2023 financials and progress towards revoking Failure to File Cease Trade Order (FFCTO). Company also reaffirms compliance with Q1 2024 financial filings

Oncology Financial Filings StageZero Life Sciences Healthcare Company FFCTO Revocation
BRIEF

published on 07/04/2024 at 00:05, 4 months 17 days ago

StageZero Life Sciences Provides Update on 2023 Financials Amid FFCTO

Ontario Securities Commission FFCTO Financial Update 2023 Financials StageZero Life Sciences
PRESS RELEASE

published on 07/04/2024 at 00:00, 4 months 17 days ago

StageZero Life Sciences Announces Update on Filing of Full Year 2023 financials under the Failure to File Cease Trade Order
StageZero Life Sciences, Ltd. provides an update on its progress toward filing full year 2023 financials. Company must complete audit and make necessary payments before the July 8th deadline to meet criteria

Financial Filing FFCTO StageZero Life Sciences MRNA Gene Expression Oncologist-led Treatment
BRIEF

published on 05/23/2024 at 22:35, 5 months 28 days ago

StageZero Life Sciences Provides Update on Cease Trade Order

Cease Trade Order Ontario Securities Commission Financial Filings StageZero Life Sciences Oncology Diagnostics
PRESS RELEASE

published on 05/23/2024 at 22:30, 5 months 28 days ago

StageZero Life Sciences Announces Update on Failure to File Cease Trade Order
StageZero Life Sciences, Ltd. remains under a Failure to File Cease Trade Order (FFCTO) following delay in filing 2023 financials. The company aims to file before July 3, 2024, and confirms no undisclosed material information

Cease Trade Order FFCTO StageZero Life Sciences Financial Delay Healthcare Company
BRIEF

published on 05/17/2024 at 22:35, 6 months 3 days ago

StageZero Life Sciences Reports Q1 2024 Financial Performance and Operational Highlights

Financial Results Cancer Diagnostics Q1 2024 Operational Highlights StageZero Life Sciences
PRESS RELEASE

published on 05/17/2024 at 22:30, 6 months 3 days ago

StageZero Life Sciences, Ltd Announces Q1 2024 Financial Results and Operational Update
StageZero Life Sciences releases Q1 2024 financial results, achieving $0.523 million in cancer testing revenue. The company updates on strategic partnerships and upcoming catalysts for 2024

Financial Results Partnerships StageZero Life Sciences 2024 Catalysts Cancer Testing Revenue
BRIEF

published on 04/05/2024 at 14:00, 7 months 16 days ago

StageZero Life Sciences Announces OSC Denial of MCTO Application

Management Cease Trade Order OSC StageZero Life Sciences Aristotle Test Telehealth Programs
PRESS RELEASE

published on 04/05/2024 at 13:55, 7 months 16 days ago

StageZero Life Sciences Provides an Update on Application for Management Cease Trade Order
StageZero Life Sciences announces denial of voluntary management cease trade order application by the Ontario Securities Commission due to anticipated delay in filing financial statements for December 31, 2023

Financial Statements Ontario Securities Commission Delay StageZero Life Sciences Voluntary Management Cease Trade Order

Accesswire

Published on 11/21/2024 at 14:00, 13 minutes ago

Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 13 minutes ago

Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 13 minutes ago

Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:00, 13 minutes ago

GameSquare's Stream Hatchet Publishes Q3 Report
Published on 11/21/2024 at 13:30, 43 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 14:00, 13 minutes ago

Form 8.3 - LOYS AG: Learning Technologies Group plc
Published on 11/21/2024 at 13:15, 58 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 38 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 58 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 2 hours 7 minutes ago

IVU AG publishes Quarterly Report Q3-2024

Les Echos

Published on 11/21/2024 at 06:58, 7 hours 15 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 53 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 28 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 28 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE